Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shire’s Vyvanse Approved For ADHD

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm will launch the drug in the second quarter pending final DEA clearance as a Schedule II controlled substance.
Advertisement

Related Content

ADHD Market Snapshot: Changes Blow In With Adderall XR Generics
ADHD Market Snapshot: Changes Blow In With Adderall XR Generics
FDA Approves Shire’s Once-daily Vyvanse For Adult ADHD
FDA Approves Shire’s Once-daily Vyvanse For Adult ADHD
No Deficit To Shire’s Top Line In ADHD
No Deficit To Shire’s Top Line In ADHD
Shire Gains Renovo’s Skin Scarring Candidate Through Licensing Deal
ADHD Drug Makers To Include Patient Medication Guides To Warn Of Cardiovascular, Psychiatric Risks
Shire Anticipates Vyvanse Approval “Any Day”
Shire Anticipates Vyvanse Approval “Any Day”

Topics

Advertisement
UsernamePublicRestriction

Register

PS065677

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel